Accelerating the development of first-in-class therapeutics against significant new drug targets to improve cancer treatment.

Clinical Trial

A Phase 1 clinical study (TACH101-CS-0001, NCT05076552) evaluating the safety, pharmacokinetics, and anti-tumor activity of TACH101, a first-in-class inhibitor of KDM4 in patients with advanced cancer is underway in several clinical centers in the United States.

Learn More

Our Science

We are targeting new pathways and mechanisms to fight cancer at its core. We combine our deep scientific foundation in molecular cancer biology, tumorigenesis, and cancer stem cell biology, with expertise in preclinical and clinical drug development to advance novel therapeutics to treat advanced cancers.

Follow the Science

Innovators in Our Field

Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal – advance our programs with speed, innovation, quality, and scientific integrity.

Meet the tachyon team

Accelerating Science for Breakthrough Therapies